A study involving several different cancer mouse models showed that treatment with mice with Toll-like receptor ligands increased the accumulation of T-cells that secreted multiple cytokines, including IL-17, delayed tumor growth and enhanced mouse survival [27]. This evidence concerns the gene IL17A and neoplasm.